“Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.”, PLoS One, vol. 8, no. 9, p. e74314, 2013.
, “Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.”, PLoS One, vol. 7, no. 4, p. e33103, 2012.
,